Ratings H.PIO Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-02 pm EDT			5-day change	1st Jan Change
3,650 ^KRW	+0.14%		-0.41%	-6.41%

May. 16	H.PIO Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	H.PIO Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

The company is in a robust financial situation considering its net cash and margin position.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 578.24 for the 2024 fiscal year.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
H.PIO CO., LTD.	-6.41%	108M		-
BELLRING BRANDS, INC.	+4.94%	7.74B		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-0.05%	5.92B		-
THE SIMPLY GOOD FOODS COMPANY	-4.67%	3.77B		B-
BYHEALTH CO., LTD	-11.92%	3.52B		D
XIAMEN KINGDOMWAY GROUP COMPANY	-10.53%	1.23B	-	-
HERBALIFE LTD.	-31.91%	1.04B		B+
SIRIO PHARMA CO., LTD.	+14.51%	988M		-
USANA HEALTH SCIENCES, INC.	-8.99%	929M		C+
JAMIESON WELLNESS INC.	-14.69%	823M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality